Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590383 | 0.98 | TRPV1 (0.46) | TRPV1CNR1CNR2CSNK1A1CRBN | |
| Hydrochloric Acid SCHEMBL3592526 | 0.97 | TRPV1 (0.45) | TRPV1CNR1CNR2CSNK1A1CRBN | |
| SCHEMBL3597009 | 0.95 | TRPV1 (0.43) | TRPV1CSNK1A1CRBNIKZF2KMT2A | |
| SCHEMBL3598505 | 0.94 | TRPV1 (0.45) | TRPV1CNR1CNR2CSNK1A1CRBN | |
| SCHEMBL3583004 | 0.94 | TRPV1 (0.43) | TRPV1CSNK1A1CRBNIKZF2KMT2A | |
| SCHEMBL13545428 | 0.91 | TRPV1 (0.43) | TRPV1CSNK1A1CRBNIKZF2 | |
| SCHEMBL3598127 | 0.91 | TRPV1 (0.42) | TRPV1CSNK1A1CRBNIKZF2 | |
| SCHEMBL13545440 | 0.91 | TRPV1 (0.43) | TRPV1CSNK1A1CRBNIKZF2 | |
| SCHEMBL3595339 | 0.91 | TRPV1 (0.42) | TRPV1CSNK1A1CRBNIKZF2KMT2A | |
| SCHEMBL3593225 | 0.89 | TRPV1 (0.43) | TRPV1CSNK1A1CRBNIKZF2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | TRPV1 2518/4885CNR1 41/4885CNR2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.